Skip to main content

ProPhase Labs, Inc.

PRPH
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0000868278

No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding ProPhase Labs, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of PRPH: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders3943+4
Shares1.96M2.69M+725.0K (+37.0%)
Value$24.9M$30.3M+$5.41M (+21.7%)

New holders (10)

Institutions that held ProPhase Labs, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to PRPH in Q3 2022
InstitutionSharesValue% of portfolio
Invesco Ltd.129,215$1.46M0.00%
American Century Companies Inc48,896$552.0K0.00%
O'Shaughnessy Asset Management, LLC40,853$461.0K0.01%
Navellier & Associates Inc40,219$454.0K0.10%
First Trust Advisors LP34,101$385.0K0.00%
Ritholtz Wealth Management20,676$233.0K0.01%
Keebeck Wealth Management, LLC20,000$226.0K0.04%
Bailard, Inc.11,200$126.0K0.01%
Occudo Quantitative Strategies LP11,158$126.0K0.01%
Covestor Ltd3,316$37.0K0.03%

Sold out (6)

Institutions that held ProPhase Labs, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of PRPH in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Virtu Financial LLC34,275$435.0K
Goldman Sachs Group Inc12,905$164.0K
Captrust Financial Advisors1,000$13.0K
Citigroup Inc720$9.00K
CoreCap Advisors, LLC100$1.00K
FMR LLC1$0